Oxford Immunotec Global PLC (OXFD) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
94C INNOVATION DRIVE ABINGDON, OX14 4RZ |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 181,270 | 192,844 | 90,332 | 59,110 | 83,715 | 50,165 | ||
| Cash and cash equivalents | 181,270 | 192,844 | 90,332 | 59,110 | 83,715 | 50,165 | ||
| Restricted cash and investments | 200 | |||||||
| Receivables | 18,329 | 13,658 | 16,981 | 13,265 | 7,058 | 6,823 | ||
| Inventory, net of allowances, customer advances and progress billings | 11,096 | 7,767 | 10,142 | 7,437 | 7,099 | 6,425 | ||
| Inventory | 11,096 | 7,767 | 10,142 | 7,437 | 7,099 | 6,425 | ||
| Contract with customer, asset | 1,600 | ✕ | ✕ | ✕ | ✕ | |||
| Other undisclosed current assets | 3,586 | 2,511 | 3,027 | 2,390 | 3,592 | 2,755 | ||
| Total current assets: | 215,881 | 216,780 | 120,482 | 82,202 | 101,464 | 66,368 | ||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 7,443 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 7,095 | 7,144 | 9,067 | 7,793 | 6,284 | 4,537 | ||
| Intangible assets, net (including goodwill) | 2,570 | 2,544 | 11,816 | 14,839 | 224 | 323 | ||
| Goodwill | 2,483 | 2,483 | 3,967 | 3,822 | 45 | 50 | ||
| Intangible assets, net (excluding goodwill) | 87 | 61 | 7,849 | 11,017 | 179 | 273 | ||
| Restricted cash and investments | 100 | 100 | 200 | 200 | 80 | 192 | ||
| Deferred income tax assets | 2,163 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Other noncurrent assets | 185 | 2,808 | 18 | 30 | ||||
| Deferred tax assets, net | ✕ | 1,052 | 2,486 | |||||
| Other undisclosed noncurrent assets | 4,500 | 16,170 | 1,782 | 2,399 | ||||
| Total noncurrent assets: | 19,371 | 15,340 | 23,754 | 41,810 | 8,388 | 7,481 | ||
| TOTAL ASSETS: | 235,252 | 232,120 | 144,236 | 124,012 | 109,852 | 73,849 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 12,816 | 13,692 | 17,976 | 17,483 | 13,748 | 12,786 | ||
| Accounts payable | 2,420 | 2,801 | 6,842 | 3,201 | 3,799 | 2,368 | ||
| Accrued liabilities | 10,396 | 10,891 | 11,134 | 14,282 | 9,949 | 7,070 | ||
| Employee-related liabilities | 3,348 | |||||||
| Deferred revenue | 19 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Debt | 984 | 85 | 91 | 84 | 79 | 137 | ||
| Business combination, contingent consideration, liability | 882 | |||||||
| Deferred revenue and credits | ✕ | ✕ | 36 | 41 | 1,654 | 1,993 | ||
| Other undisclosed current liabilities | 4,231 | 4,342 | (3,348) | |||||
| Total current liabilities: | 13,819 | 18,008 | 22,445 | 18,490 | 15,481 | 11,568 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 7,742 | 106 | 29,904 | 29,601 | 386 | 454 | ||
| Long-term debt, excluding current maturities | 32 | 106 | 29,904 | 29,601 | 386 | 454 | ||
| Operating lease, liability | 7,710 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 364 | 2,957 | 1,293 | 1,218 | ||||
| Other liabilities | 364 | 364 | ||||||
| Business combination, contingent consideration, liability | 2,593 | 1,293 | 1,218 | |||||
| Other undisclosed noncurrent liabilities | 3,894 | |||||||
| Total noncurrent liabilities: | 7,742 | 106 | 34,162 | 32,558 | 1,679 | 1,672 | ||
| Total liabilities: | 21,561 | 18,114 | 56,607 | 51,048 | 17,160 | 13,240 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 213,691 | 214,006 | 87,629 | 72,964 | 92,692 | 60,609 | ||
| Common stock | 276 | 276 | 269 | 243 | 243 | 192 | ||
| Additional paid in capital | 304,909 | 303,015 | 294,613 | 249,128 | 244,033 | 186,816 | ||
| Accumulated other comprehensive loss | (7,461) | (8,523) | (5,712) | (7,751) | (5,277) | (4,570) | ||
| Accumulated deficit | (84,033) | (80,762) | (201,541) | (168,656) | (146,307) | (121,829) | ||
| Total stockholders' equity: | 213,691 | 214,006 | 87,629 | 72,964 | 92,692 | 60,609 | ||
| TOTAL LIABILITIES AND EQUITY: | 235,252 | 232,120 | 144,236 | 124,012 | 109,852 | 73,849 | ||
Income Statement (P&L) ($ in thousands) Annual | Quarterly
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 73,710 | 59,753 | 103,080 | 86,078 | 62,782 | 49,505 | |
| Revenue, net | ✕ | ✕ | 103,080 | 86,078 | 62,782 | 49,505 | |
| Cost of revenue | (19,288) | (16,826) | (46,731) | (39,472) | (29,544) | (24,009) | |
| Cost of goods and services sold | (19,288) | (16,826) | (46,731) | (39,472) | (29,544) | (24,109) | |
| Gross profit: | 54,422 | 42,927 | 56,349 | 46,606 | 33,238 | 25,496 | |
| Operating expenses | (60,545) | (63,646) | (109,936) | (72,583) | (57,414) | (47,357) | |
| Operating loss: | (6,123) | (20,719) | (53,587) | (25,977) | (24,176) | (21,861) | |
| Nonoperating income (expense) | (1,881) | (160) | (2,059) | 718 | (89) | (107) | |
| Foreign currency transaction gain (loss), before tax | (1,949) | 111 | (1,850) | 1,364 | (143) | (352) | |
| Other nonoperating income (expense) | 68 | (271) | (209) | (646) | 54 | 245 | |
| Interest and debt expense | (2,105) | ||||||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 4,247 | (1,797) | 24,395 | (864) | (67) | ||
| Loss from continuing operations before equity method investments, income taxes: | (3,757) | (24,781) | (31,251) | (26,123) | (24,332) | (21,968) | |
| Other undisclosed loss from continuing operations before income taxes | (52) | ||||||
| Loss from continuing operations before income taxes: | (3,757) | (24,781) | (31,251) | (26,123) | (24,332) | (22,020) | |
| Income tax expense (benefit) | 2,417 | 37,286 | (1,634) | 3,774 | (146) | (154) | |
| Income (loss) from continuing operations: | (1,340) | 12,505 | (32,885) | (22,349) | (24,478) | (22,174) | |
| Income (loss) from discontinued operations | (469) | 108,274 | |||||
| Net income (loss) available to common stockholders, diluted: | (1,809) | 120,779 | (32,885) | (22,349) | (24,478) | (22,174) | |
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (1,809) | 120,779 | (32,885) | (22,349) | (24,478) | (22,174) | |
| Other comprehensive loss | (151) | (2,474) | (707) | (822) | |||
| Comprehensive income (loss): | (1,960) | 120,779 | (32,885) | (24,823) | (25,185) | (22,996) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 1,213 | (2,811) | 2,039 | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | (747) | 117,968 | (30,846) | (24,823) | (25,185) | (22,996) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.